[26] | 1999-2004 | Hospitalized patients’ surgical and burn wounds, pus/abscess, upper respiratory tract and urine had culture obtained | 1997 | 416 (20.8) | No genotypic characterization data reported. |
Outpatients’ surgical and burn wounds, pus/abscess, upper respiratory tract and urine had culture obtained | 433 | 35 (8.1) | No genotypic characterization data reported | ||
[28] | 2013-2014 | Hospitalized patients’ clinical samples had culture obtained | 294 | 45 (15.31) | MRSA ST239 SCCmec III (60%) ST8 SCCmec IV (37.78%); PVL +, “USA300” SCCmec V (2.22%); ACME− positive “Staphylococcus argenteus” lineages (2.38%) MSSA PVL− positive CC8-MSSA (20.41%) “African” PVL− positive CC152-MSSA (9.52%) PVL− positive CC30-MSSA (8.84%) |
[29] | 2016 | Outpatients’ anterior nares and wound swabs had culture obtained | 36 | 16 (44.4) | SCCmec IV (75%); PVL + SCCmec V (25%) |
[30] | 2011 | Hospitalized patients’ skin lesion, surgical wounds, blood and bronchial secretions had culture obtained | Data not provided. | 87 | ST8 t008 SCCmec IVa (67.8%) PVL+, ACME+ ST8 t008 SCCmec IVa (13.8%) PVL+, ACME− ST8 t008 SCCmec IVa (1.2%) PVL−, ACME− ST8 t211 IVa (3.6%) PVL+, ACME+ ST72 t13567 SCCmec V (12.6%) PVL−, ACME− ST72 t13567 SCCmec V (1.2%) PVL+, ACME− |
[31] | 2012 | Hospitalized patients’ and staff’s anterior nares had cultures obtained | 16 | 4 (25%) | t148, CC72, SCCmec IV (50%) t002, CC5, SCCmec II (25% t002, CC5, SCCmec IV (25%) |
[32] | 2017-2018 | Hospitalized patients’ samples from pus, nasal cavity, wounds, catheters, blood, skin urine had cultures obtained | 119 | 54 (45.4%) | ST8 SCCmec IV (88%) “USA300-NAE lineage” ST5 (2.9%) ST4080 (2.9%) ST30-MRSA-V (1.5%) |
Hospital staffs’ nasal samples had cultures obtained | 33 | 15 (42.42%) | ST72 (1.5%) ST121 (1.5%) ST134 (1.5%) | ||
[33] | 2013 | Hospitalized patients’ surgical wounds had culture obtained | 38 | 15 (39.5) | No genotypic characterization reported |